お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959723

再生医療の世界市場における分析と予測:幹細胞・組織工学・バイオバンキング・CAR-T業界

Global Regenerative Medicine Market Analysis & Forecast to 2025: Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

出版日: | 発行: Kelly Scientific Publications | ページ情報: 英文 700 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
再生医療の世界市場における分析と予測:幹細胞・組織工学・バイオバンキング・CAR-T業界
出版日: 2020年09月07日
発行: Kelly Scientific Publications
ページ情報: 英文 700 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界における再生医療の市場規模は、2019年の350億米ドルから、2025年までに1240億米ドル以上へ拡大すると予測され、この間は23.3%のCAGRが見込まれています。

当レポートでは、世界の再生医療市場について調査し、市場規模の包括的な概要、セグメント別の分析 (幹細胞・組織工学・バイオバンキング・CAR-T)、主要企業、および臨床試験中の治療の可能性などについて分析しています。

目次

第1章 レポートの要約

  • レポートの目的
  • エグゼクティブサマリー
  • このレポートで回答された主な質問
  • データソースと調査手法

第2章 イントロダクション

  • Gurdon氏と山中氏がノーベル賞を共同で受賞
  • 幹細胞臨床試験:2010年に開始
  • 幹細胞の種類
  • 成体(組織)幹細胞
  • 多能性幹細胞
  • 体細胞核移植(SCNT)
  • 人工多能性幹細胞(iPSC)
  • 間葉系細胞
    • 骨髄間質のMSC
    • MSCの分離、マーカーの特異性、機能特性
    • 酸素濃度とMSC培養
    • MSCを定義するためのアッセイ
    • MSCの分化の可能性
    • MSCの治療上の可能性
    • 間葉系幹細胞および慢性疾患
    • MSCおよびアミロトロフィー性側索硬化症
    • MSCおよびパーキンソン病
    • MSCおよびアルツハイマー病
    • MSCおよび関節リウマチ
    • MSCおよび1型糖尿病
    • MSCおよび心血管疾患
  • 造血幹細胞と前駆細胞
    • 造血幹細胞のin Vivoアッセイ
    • 造血幹細胞および前駆細胞のin Vitroアッセイ
    • 造血幹細胞および前駆細胞の分離
    • 造血細胞の培養
    • 造血細胞の治療的使用
  • 臍帯幹細胞
  • 心臓幹細胞
    • 心臓幹細胞の最先端調査
  • 乳腺幹細胞
    • 乳腺幹細胞の定義
    • 幹細胞の同定に対するモデルシステムの影響
    • 乳がん幹細胞
  • 神経幹細胞
    • 神経幹細胞の同定
    • In Vivoにおける神経幹細胞の機能
    • 神経幹細胞培養システム
    • 神経幹細胞の分離戦略
    • 脳腫瘍幹細胞
    • 神経幹細胞の最先端調査
  • 網膜修復における幹細胞アプリケーション
    • 網膜治療薬としての胚性幹細胞
    • 網膜治療薬としての多能性幹細胞の誘導
    • 脂肪は、網膜治療薬として間葉系幹細胞を派生
  • 肝幹細胞
  • 腸幹細胞
  • 膵臓幹細胞
  • 表皮幹細胞

第3章 幹細胞と臨床試験

  • イントロダクション
  • 多能性幹細胞
  • 辺縁幹細胞
  • 神経幹細胞
  • 内皮幹細胞または前駆細胞
  • 胎盤幹細胞
  • 幹細胞臨床試験が失敗するのはなぜか?
  • 幹細胞試験の未来とは?
  • 最先端の幹細胞臨床試験
  • Ocata Therapeutics:現在の幹細胞試験
  • CHA Biotech:現在の幹細胞試験
  • Pfizer :現在の幹細胞試験
  • GSK :現在の幹細胞試験
  • Bayer :現在の幹細胞試験
  • Mesoblast International :現在の幹細胞試験
  • Millennium Pharmaceutical Current Stem Cell Trial
  • AstraZeneca :現在の幹細胞試験
  • Merck :現在の幹細胞試験
  • Chimerix :現在の幹細胞試験
  • エーザイ :現在の幹細胞試験
  • SanBio :現在の幹細胞試験
  • Celgene :現在の幹細胞試験
  • StemCells :現在の幹細胞試験
  • Genzyme (Sanofi) :現在の幹細胞試験
  • Teva :現在の幹細胞試験
  • MedImmune :現在の幹細胞試験
  • Janssen :現在の幹細胞試験
  • Seattle Genetics :現在の幹細胞試験
  • Baxter Healthcare :現在の幹細胞試験
  • InCyte Corp :現在の幹細胞試験

第4章 幹細胞、破壊的技術、創薬および毒性試験

  • イントロダクション
  • ケーススタディ:Genentechと幹細胞技術
  • 3D球体文化システム
  • 幹細胞とハイスループットスクリーニング
    • 胚性幹細胞
    • 成体幹細胞
    • 市場機会と課題
  • 幹細胞の遺伝的不安定性
  • 包括的インビトロ漿液性不整脈アッセイ(CiPA)と心筋細胞
  • Precise Genome Editing(PGE)とiPSCの結合
  • 幹細胞と毒性試験
    • 肝毒性とiPSC
    • 心毒性とiPSC
    • 神経毒性とiPSC
  • 幹細胞疾患モデル
  • 人間の病気特有の表現型の定義
    • 疾患モデリングのための分子表現型
    • 疾患モデリングのための細胞表現型
    • 疾患モデリングのための生理学的表現型
    • パーキンソン病
    • アルツハイマー病
    • 筋萎縮性側索硬化症
    • ハンチントン病
    • 脊髄性筋萎縮症
    • ダウン症
    • 嚢胞性線維症
    • 大腸がん
  • 薬物スクリーニングにおける幹細胞由来の細胞と組織の利点

第5章 幹細胞バイオマーカー

  • 多能性幹細胞バイオマーカー
  • 間葉系幹細胞バイオマーカー
  • 神経幹細胞バイオマーカー
  • 造血幹細胞バイオマーカー

第6章 幹細胞製品の製造

  • 幹細胞製品の製造戦略
  • 幹細胞製品のバイオプロセス経済学
  • 設備投資
  • 商品価格
  • バイオプロセスの経済的推進力と戦略
  • プレーナ技術を使用したhPSCの拡張と差別化
  • 3Dカルチャーを使用したhPSC拡張
  • マイクロキャリアシステム
  • 凝集サスペンション
  • バイオリアクターに基づく分化戦略
  • 統合型hPSCバイオプロセス戦略
  • GMP規制と幹細胞製品

第7章 投資と資金調達

  • 投資家は細胞および遺伝子治療企業に何を望んでいるか?
  • 良い投資とは何か?
  • どのタイプの企業が投資を受けないのか?
  • 世界の資金
  • 今後の細胞と遺伝子治療への投資
  • 2018年に最も有望な細胞および遺伝子企業とは?
  • 細胞および遺伝子治療企業への投資に関する考察

第8章 再生医療市場分析&2025年までの予測

  • 市場概要
  • 世界の頻度分析
  • 再生医療の経済学
  • 再生療法の市場アプリケーションと機会
    • 神経疾患
    • 自己免疫疾患
    • 循環器疾患
    • 糖尿病
    • 筋骨格障害
    • 眼疾患
    • 整形外科疾患
    • 創傷治癒
  • 世界の金融情勢
  • 再生医療臨床試験統計
  • 予測される再生医療市場
  • 再生医療の地域分析と予測
  • 企業の再生医療地理的位置
  • 企業の再生医療技術の内訳
  • 市販の再生医療製品
  • 主な再生医療のマイルストーン

第9章 幹細胞市場分析&予測

  • 自家および同種細胞の市場分析
  • 地域別幹細胞市場
    • 北米
    • アジア太平洋
    • 欧州
  • 治療適応別幹細胞市場予測
    • 整形外科/筋骨格幹細胞2次市場
    • 癌幹細胞2次市場
    • 循環器/血管幹細胞2次市場分析
    • 創傷治癒幹細胞2次市場分析
    • 皮膚幹細胞2次市場分析
    • 眼幹細胞2次市場予測
  • 幹細胞試薬の市場動向

第10章 組織工学市場分析と予測

  • 地域分析と予測
    • 北米
    • 欧州
    • アジア太平洋
  • 地域分析:企業シェア
  • 組織工学の臨床適応症の分析と予測
    • 整形外科および筋骨格
    • 腫瘍学
    • 循環器および血管
    • 皮膚科
    • 口腔および歯科

第11章 バイオバンキング市場分析

  • 世界的に増加する臍帯血バンクの数
  • 世界のバイオバンキング企業のセクター分析と内訳
  • 同種対自家移植頻度
  • バイオバンキング市場分析と予測
  • 世界の主要企業

第12章 世界の再生医療市場におけるアクセスと課題

  • 米国の再生医療市場
  • 日本の再生医療
    • 金融投資
    • 再生医療への型破りな企業の投資
  • 中国の再生医療
  • 韓国の再生医療

第13章 細胞およびCAR T療法

  • 免疫療法における細胞療法およびキメラ抗原受容体T細胞に関する課題
    • これまでのCD19 CAR-T細胞の臨床状態
    • CAR T細胞の開発のための臨床的および規制上の課題
    • CAR-T開発に関連する規制上の主な課題
    • Juno、Novartis、KiteによるCAR-T製品の概要
    • CD19が指示するすべての臨床試験における毒性と毒性の対比
    • CAR-T療法の毒性を管理する方法
  • 米国における養子細胞療法(CAR-TおよびTCR)免疫療法規制を含む、免疫療法に関する規制
    • 生物学的製剤評価研究センター(CBER)
    • コンプライアンスと監視
    • FDAの免疫療法に関する追加リソース
    • 細胞、組織および遺伝子治療諮問委員会
    • FDAの消費者支部(CBER)連絡先
    • 免疫療法に関するFDA規制
    • ケーススタディ:卵巣がん免疫療法規制
    • 免疫療法に関する試験設計の考慮事項
    • 免疫関連応答基準(irRC)の開発&免疫療法に固有の臨床エンドポイント
  • 日本の細胞療法および免疫療法に関する規制
    • PMDAおよび細胞療法および免疫療法
    • 細胞療法および免疫療法規制レビューの効率の向上
    • フォアランナーレビュー割り当てシステム
    • 抗悪性腫瘍剤の臨床評価のためのガイドライン改訂
    • 細胞療法および免疫療法のためのPMDA内の主要な連絡先
  • 欧州の規制と細胞療法および免疫療法
    • イントロダクション
    • 欧州・中東・アフリカにおける細胞療法および免疫療法の課題
    • 効力試験に関するEMAステータス
    • ハイパー、ハイポ、または非レスポンダーの識別に関するEMAステータス
    • 免疫療法におけるバイオマーカーに関する課題
    • 免疫療法におけるキメラ抗原受容体T細胞に関する課題
    • 最適なカットオフパラメーターの推定
    • メラノーマにおけるEU承認の免疫療法
    • 細胞療法および免疫療法のためのEMA内の主要な連絡先
  • 免疫療法の製造
    • イントロダクション
    • CAR修飾T細胞の生成
    • どの共同刺激と活動領域が使用に最適か?
    • 細胞培養培地の最適化
    • レンチウイルスベクターの製造
    • 統合されたCAR発現ベクターの検出
    • ドナーリンパ球注入手順
    • Ex Vivo共刺激&ドナーT細胞の拡大
    • 患者への注入
    • 免疫療法の生産に必要な製造装置と機器
    • 免疫療法のための良い製造手順(GMP)
    • ケーススタディGMP条件下でのレンチウイルス誘発樹状細胞の産生
    • 品質管理
    • 薬事
    • 製造における主な課題
    • 細胞療法製造における自動化
    • 自家細胞療法製造スケールアップ
  • サプライチェーンとロジスティクス
    • イントロダクション
    • ケーススタディ:Juno Therapeutics
  • 価格とコスト分析
    • イントロダクション
    • CAR T療法の市場評価
    • CAR T市場内の現在の取引
  • CAR-T療法と固形腫瘍
    • 固形腫瘍の課題
    • 腫瘍微小環境内での免疫抑制の回避
    • 有望な臨床試験

第14章 企業プロファイル

  • Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
  • Athersys
  • Baxter International (Baxalta, Shire)
  • Caladrius Biosciences(NeoStem)
  • Cynata Therapeutics
  • Cytori Therapeutics
  • MEDIPOST
  • Mesoblast
  • NuVasive
  • Osiris Therapeutics
  • Plasticell
  • Pluristem Therapeutics
  • Pfizer
  • StemCells Inc
  • STEMCELL Technologies
  • タカラバイオ
  • Tigenix

第15章 SWOT産業分析

  • これまでに業界を強化したものは何か?
  • 同種および自家幹細胞産業のSWOT分析
  • この領域の主な原動力は何か?
  • 全体としての再生医療産業の抑制要因
  • このセクター内の産業機会
  • 米国のSWOT分析
    • 成長機会
    • 促進要因
    • 市場の課題
  • 英国のSWOT分析
  • 韓国のSWOT分析
  • 中国のSWOT分析
  • 日本のSWOT分析
  • シンガポールのSWOT分析
目次
Product Code: 2020RM

This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $35 billion in 2019 and will grow to over $124 billion by 2025, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2025. Tissue engineering is forecast to grow at a CAGR of x% to 2025 and potentially reach $x billion.

This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 700 pages.

  • An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
  • Global regenerative medicine market, global breakdown, application breakdown and leading market players
  • Detailed account of the stem cell industry market by geography, indication and company profiles
  • Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
  • Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
  • Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe

Table of Contents

1.0 Report Synopsis

  • 1.1 Objectives of Report
  • 1.2 Executive Summary
  • 1.2 Key Questions Answered in this Report
  • 1.3 Data Sources and Methodology

2.0 Introduction

  • 2.1 Gurdon and Yamanaka Share the Nobel Prize
  • 2.2 Stem Cell Clinical Trials: Initiated in 2010
  • 2.3 Types of Stem Cells
  • 2.4 Adult (Tissue) Stem Cells
  • 2.5 Pluripotent Stem Cells
  • 2.6 Somatic Cell Nuclear Transfer (SCNT)
  • 2.7 Induced pluripotent Stem Cells (iPSC)
  • 2.8 Mesenchymal Cells
    • 2.8.1 MSCs in the Bone Marrow Stroma
    • 2.8.2 Isolation, Marker Specificity and Functional Properties of MSCs
    • 2.8.3 Oxygen Concentration and MSC Culture
    • 2.8.4 Assays to Define MSCs
    • 2.8.5 Differentiation Potential of MSCs
    • 2.8.6 Therapeutic Potential of MSCs
    • 2.8.7 Mesenchymal Stem Cells & Chronic Disease
    • 2.8.8 MSCs and Amylotrophic Lateral Sclerosis
    • 2.8.9 MSCs and Parkinson's Disease
    • 2.8.10 MSCs and Alzheimer Disease
    • 2.8.11 MSCs and Rheumatoid Arthritis
    • 2.8.12 MSCs and Type 1 Diabetes
    • 2.8.13 MSCs and Cardiovascular Disease
  • 2.9 Hematopoietic Stem and Progenitor Cells
    • 2.9.1 In Vivo Assays for Hematopoietic Stem Cells
    • 2.9.2 In Vitro Assays for Hematopoietic Stem and Progenitor Cells
    • 2.9.3 Isolation of Hematopoietic Stem and Progenitor Cells
    • 2.9.4 Culture of Hematopoietic Cells
    • 2.9.5 Therapeutic uses of Hematopoietic Cells
  • 2.10 Umbilical Cord Stem Cells
  • 2.11 Heart Stem Cells
    • 2.11.1 Cutting Edge Research in Heart Stem Cells
  • 2.12 Mammary Stem Cells
    • 2.12.1 Defining the Mammary Stem Cell
    • 2.12.2 Influence of Model System on Stem Cell Identification
    • 2.12.3 Breast Cancer Stem Cells
  • 2.13 Neural Stem Cells
    • 2.13.1 Identification of Neural Stem Cells
    • 2.13.2 Function of Neural Stem Cells in Vivo
    • 2.13.3 Neural Stem Cell Culture Systems
    • 2.13.4 Isolation Strategies for Neural Stem Cells
    • 2.13.5 Brain Tumour Stem Cells
    • 2.13.6 Cutting Edge Research in Neural Stem Cells
  • 2.14 Stem Cell Applications in Retinal Repair
    • 2.14.1 Embryonic Stem Cells as Retina Therapeutics
    • 2.14.2 Induced Pluripotent Stem Cells as Retina Therapeutics
    • 2.14.3 Adipose Derived Mesenchymal Stem Cells as Retina Therapeutics
  • 2.15 Liver Stem Cells
  • 2.16 Gut Stem Cells
  • 2.16 Pancreatic Stem Cells
  • 2.17 Epidermal Stem Cells

3.0 Stem Cells and Clinical Trials

  • 3.1 Introduction
  • 3.2 Pluripotent Stem Cells
  • 3.3 Limbal Stem Cells
  • 3.4 Neural Stem Cells
  • 3.5 Endothelial Stem or Progenitor Cells
  • 3.6 Placental Stem Cells
  • 3.7 Why Do Stem Cell Clinical Trials Fail?
  • 3.8 What is the Future of Stem Cell Trials?
  • 3.9 Cutting Edge Stem Cell Clinical Trials
  • 3.10 Ocata Therapeutics Current Stem Cell Trials
  • 3.11 CHA Biotech Current Stem Cell Trials
  • 3.12 Pfizer Current Stem Cell Trials
  • 3.13 GSK Current Stem Cell Trials
  • 3.14 Bayer Current Stem Cell Trials
  • 3.15 Mesoblast International Current Stem Cell Trials
  • 3.16 Millennium Pharmaceutical Current Stem Cell Trial
  • 3.17 AstraZeneca Current Stem Cell Trials
  • 3.18 Merck Current Stem Cell Trials
  • 3.19 Chimerix Current Stem Cell Trials
  • 3.20 Eisai Current Stem Cell Trials
  • 3.21 SanBio Current Stem Cell Trials
  • 3.22 Celgene Current Stem Cell Trials
  • 3.23 StemCells Current Stem Cell Trials
  • 3.24 Genzyme (Sanofi) Current Stem Cell Trials
  • 3.25 Teva Current Stem Cell Trials
  • 3.26 MedImmune Current Stem Cell Trials
  • 3.27 Janssen Current Stem Cell Trials
  • 3.28 Seattle Genetics Current Stem Cell Trials
  • 3.29 Baxter Healthcare Current Stem Cell Trials
  • 3.30 InCyte Corp Current Stem Cell Trials

4.0 Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing

  • 4.1 Introduction
  • 4.2 Case Study: Genentech and Stem Cell Technology
  • 4.3 3D Sphere Culture Systems
  • 4.4 Stem Cells and High Throughput Screening
    • 4.4.1 Embryonic Stem Cells
    • 4.4.2 Adult Stem Cells
    • 4.4.3 Opportunities & Challenges
  • 4.5 Genetic Instability of Stem Cells
  • 4.6 Comprehensive in Vitro Proarrhythmia Assay (CiPA) & Cardiomyocytes
  • 4.8 Coupling Precise Genome Editing (PGE) and iPSCs
  • 4.9 Stem Cells & Toxicity Testing
    • 4.9.1 Hepatotoxicity and iPSCs
    • 4.9.2 Cardiotoxicity and iPSCs
    • 4.9.3 Neurotoxicity and iPSCs
  • 4.10 Stem Cell Disease Models
  • 4.11 Defining Human Disease Specific Phenotypes
    • 4.11.1 Molecular Phenotypes for Disease Modelling
    • 4.11.2 Cellular Phenotypes for Disease Modelling
    • 4.11.3 Physiological Phenotypes for Disease Modelling
    • 4.11.4 Parkinson's Disease
    • 4.11.5 Alzheimer's Disease
    • 4.11.6 Amyotrophic Lateral Sclerosis
    • 4.11.7 Huntington's Disease
    • 4.11.8 Spinal Muscular Atrophy
    • 4.11.9 Down Syndrome
    • 4.11.10 Cystic Fibrosis
    • 4.11.11 Colorectal Cancer
  • 4.12 Advantages of Stem Cell Derived Cells & Tissues for Drug Screening

5.0 Stem Cell Biomarkers

  • 5.1 Pluripotent Stem Cell Biomarkers
  • 5.2 Mesenchymal Stem Cell Biomarkers
  • 5.3 Neural Stem Cell Biomarkers
  • 5.4 Hematopoietic Stem Cell Biomarkers

6.0 Manufacturing Stem Cell Products

  • 6.1 Manufacturing Strategies For Stem Cell Products
  • 6.2 BioProcess Economics for Stem Cell Products
  • 6.3 Capital Investment
  • 6.4 Cost of Goods
  • 6.5 Bioprocess Economic Drivers & Strategies
  • 6.6 hPSC Expansion & Differentiation using Planar Technology
  • 6.7 hPSC Expansion using 3D Culture
  • 6.8 Microcarrier Systems
  • 6.9 Aggregate Suspension
  • 6.10 Bioreactor Based Differentiation Strategy
  • 6.11 Integrated hPSC Bioprocess Strategy
  • 6.12 GMP Regulations and Stem Cell Products

7.0 Investment & Funding

  • 7.1 What do Investors Want from Cell & Gene Therapy Companies?
  • 7.2 What Makes a Good Investment?
  • 7.3 What Types of Companies do Not Get Investment?
  • 7.4 Global Funding
  • 7.5 Cell & Gene Therapy Investment Going Forward
  • 7.6 What Cell & Gene Companies are the Most Promising in 2018?
  • 7.7 Insights into Investing in Cell and Gene Therapy Companies

8.0 Regenerative Medicine Market Analysis & Forecast to 2025

  • 8.1 Market Overview
  • 8.2 Global Frequency Analysis
  • 8.3 Economics of Regenerative Medicine
  • 8.4 Market Applications & Opportunities for Regenerative Therapies
    • 8.4.1 Neurological Disease
    • 8.4.2 Autoimmune Disorders
    • 8.4.3 Cardiovascular Disease
    • 8.4.4 Diabetes
    • 8.4.5 Musculoskeletal Disorders
    • 8.4.6 Ocular Disease
    • 8.4.7 Orthopedic Disorders
    • 8.4.8 Wound Healing
  • 8.5 Global Financial Landscape
  • 8.6 Regenerative Medicine Clinical Trial Statistics
  • 8.7 Regenerative Medicine Market Forecast to 2025
  • 8.8 Regenerative Medicine Geographic Analysis and Forecast to 2025
  • 8.9 Regenerative Medicine Geographical Location of Companies
  • 8.10 Regenerative Medicine Technology Breakdown of Companies
  • 8.11 Commercially Available Regenerative Medicine Products
  • 8.12 Major Regenerative Medicine Milestones

9.0 Stem Cell Market Analysis & Forecast to 2025

  • 9.1 Autologous & Allogenic Cell Market Analysis
  • 9.2 Stem Cell Market by Geography
    • 9.2.1 North America
    • 9.2.2 Asia/Pacific
    • 9.2.3 Europe
  • 9.3 Stem Cell Market Forecast by Therapeutic Indication
    • 9.3.1 Orthopedic/Musculoskeletal Stem Cell SubMarket
    • 9.3.2 Cancer Stem Cell SubMarket
    • 9.3.3 Cardiology/Vascular Stem Cell SubMarket Analysis
    • 9.3.4 Wound Healing Stem Cell SubMarket Analysis
    • 9.3.5 Skin Stem Cell SubMarket Analysis
    • 9.3.6 Ocular Stem Cell SubMarket Forecast
  • 9.4 Stem Cell Reagent Market Trends

10.0 Tissue Engineering Tissue Engineering Market Analysis and Forecast to 2025

  • 10.1 Geographical Analysis and Forecast to 2025
    • 10.1.1 North America
    • 10.1.2 Europe
    • 10.1.3 Asia Pacific
  • 10.2 Geographical Analysis by Company Share
  • 10.3 Tissue Engineering Clinical Indication Analysis & Forecast to 2025
    • 10.3.1 Orthopedic and Musculoskeletal
    • 10.3.2 Oncology
    • 10.3.3 Cardiology and Vascular
    • 10.3.4 Dermatology
    • 10.3.5 Oral and Dental

11.0 Biobanking Market Analysis

  • 11.1 Increasing Number of Cord Blood Banks Globally
  • 11.2 Global Biobanking Company Sector Analysis & Breakdown
  • 11.3 Allogenic Versus Autologous Transplant Frequency
  • 11.4 Biobanking Market Analysis & Forecast to 2025
  • 11.5 Major Global Players

12.0 Global Access & Challenges of the Regenerative Medicine Market

  • 12.1 Regenerative Medicine Market in the USA
  • 12.2 Regenerative Medicine in Japan
    • 12.2.1 Financial Investment
    • 12.2.2 Unconventional Company Investment in Regenerative Medicine
  • 12.3 Regenerative Medicine in China
  • 12.4 Regenerative Medicine in South Korea

13.0 Cell and CAR T Therapy

  • 13.1 Challenges Relating to Cell therapy and Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.1.1 Clinical Status of CD19 CAR-T Cells To Date
    • 13.1.2 Clinical and Regulatory Challenges for Development of CAR T Cells
    • 13.1.3 Key Regulatory Challenges Associated with CAR-T Development
    • 13.1.4 Summary of Select CAR-T Products by Juno, Novartis and Kite
    • 13.1.5 Clinical Benefit Versus Toxicity in CD19-Directed ALL Clinical Trials
    • 13.1.6 How to Manage Toxicity of CAR-T Therapy
  • 13.2 Regulations Pertaining to Immunotherapy, including Adoptive Cell Therapy (CAR-T and TCR) Immunotherapy Regulation in the USA
    • 13.2.1 Center for Biologics Evaluation and Research (CBER)
    • 13.2.2 Compliance and Surveillance
    • 13.2.3 Extra Resources on Immunotherapeutics from the FDA
    • 13.2.4 Cellular, Tissue and Gene Therapies Advisory Committee
    • 13.2.5 Consumer Affairs Branch (CBER) Contact in FDA
    • 13.2.6 FDA Regulations Pertaining to Immunotherapies
    • 13.2.7 Case Study Ovarian Cancer Immunotherapy Regulations
      • 13.2.7.1 Efficacy
      • 13.2.7.2 Adverse Effects
    • 13.2.8 Trial Design Considerations for Immunotherapy
    • 13.2.9 Development of Immune-Related Response Criteria (irRC) & Clinical Endpoints Specific to Immunotherapies
  • 13.3 Regulations for Cell Therapy & Immunotherapy in Japan
    • 13.3.1 PMDA and Cell Therapy & Immunotherapy
    • 13.3.2 Increasing the Efficiency in Cell Therapy & Immunotherapy Regulatory Review
    • 13.3.3 Forerunner Review Assignment System
    • 13.3.4 Revised Guidelines for Clinical Evaluation of Anti-Malignant Tumor Agents
    • 13.3.5 Key Contacts Within the PMDA for Cell Therapy & Immunotherapeutics
  • 13.4 European Regulation and Cell Therapy & Immunotherapeutics
    • 13.4.1 Introduction
    • 13.4.2 Challenges for Cell Therapy & Immunotherapy in EMEA
    • 13.4.3 EMA Status on Potency Testing
      • 13.4.3.1 In Vivo Potency Testing
      • 13.4.3.2 In Vitro Potency Testing
      • 13.4.3.3 Viable Cell Count
      • 13.4.3.4 Autologous Cell Based Products
      • 13.4.3.5 Reference Preparation
      • 13.4.3.6 Adjuvant Containing Immunotherapy Products
    • 13.4.4 EMA Status on Identifying hyper, Hypo or non-Responders
    • 13.4.5 Challenges Relating to Biomarkers in Immunotherapy
    • 13.4.6 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.4.7 Estimating Optimal Cut-Off Parameters
    • 13.4.8 EU-Approved Immunotherapies in Melanoma
    • 13.4.9 Key Contacts Within EMA for Cell Therapy & Immunotherapeutics
  • 13.5 Manufacturing of Immunotherapies
    • 13.5.1 Introduction
    • 13.5.2 Generation of CAR-Modified T Cells
    • 13.5.3 What Co-Stimulation and Activity Domain is Optimal to Use?
    • 13.5.4 Optimizing Cell Culture Media
    • 13.5.5 Manufacturing Lentiviral Vectors
    • 13.5.6 Detection of Integrated CAR-Expressing Vectors
    • 13.5.7 Donor Lymphocyte Infusion Procedure
    • 13.5.8 Ex Vivo Costimulation & Expansion of Donor T Cells
    • 13.5.9 Infusion to the Patient
    • 13.5.10 Manufacturing Devices and Instruments Required for Immunotherapy Production
      • 13.5.10.1 Leukapheresis
      • 13.5.10.2 Cell Counters and Analyzer
      • 13.5.10.3 Cell Seeding, Growth and Propagation
    • 13.5.11 Good Manufacturing Procedure (GMP) for Immunotherapy
    • 13.5.12 Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions
    • 13.5.13 Quality Control
    • 13.5.14 Regulatory Affairs
    • 13.5.15 Key Challenges in Manufacturing
      • 13.5.15.1 Electroporation of T-cells
      • 13.5.15.2 Allogenic CAR T cells
      • 13.5.15.3 Relapse Rates are Critical
      • 13.5.15.4 Antigen Negative Relapse
      • 13.5.15.5 Incorporating Suicide Genes
    • 13.5.16 Automation in Cell Therapy Manufacturing
    • 13.5.17 Autologous Cell Therapy Manufacture Scale Up
  • 13.6 Supply Chain & Logistics
    • 13.6.1 Introduction
    • 13.6.2 Case Study: Juno Therapeutics
  • 13.7 Pricing & Cost Analysis
    • 13.7.1 Introduction
    • 13.7.2 CAR T Therapy Market Evaluation
    • 13.7.3 Current Deals Within the CAR T Market
  • 13.8 CAR-T Therapy and Solid Tumors
    • 13.8.1 Challenges for Solid Tumors
      • 13.8.1.1 Off-Tumor Toxic Responses
      • 13.8.1.2 Poor Penetration to Tumor Site
      • 13.8.1.3 Increasing Therapeutic Efficiency
    • 13.8.2 Avoiding Immunosuppression within Tumor Microenvironment
    • 13.8.3 Clinical Trials Show Promise

14.0 Company Profiles

  • 14.1 Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
    • 14.1.1 Company Background
    • 14.1.2 Products
    • 14.1.3 Financials
    • 14.1.4 Company Strategy
  • 14.2 Athersys
    • 14.2.1 Company Background
    • 14.2.2 Products
    • 14.2.3 Financial Analysis
    • 14.2.4 Company Strategy
  • 14.3 Baxter International (Baxalta, Shire)
    • 14.3.1 Company Background
    • 14.3.2 Financial Analysis
    • 14.3.3 Company Strategy
  • 14.4 Caladrius Biosciences (NeoStem)
    • 14.4.1 Company Details
    • 14.4.2 Products
      • 14.4.2.1 CLBS20
      • 14.4.2.2 CLBS03 Treg Cellular Therapy
      • 14.4.2.3 CLBS12 CD34 Cell Therapy
    • 14.4.3 Financial Analysis
    • 14.4.4 Company Strategy
  • 14.5 Cynata Therapeutics
    • 14.5.1 Company Background
    • 14.5.2 Product Details
    • 14.5.3 Financial Data
    • 14.5.4 Company Strategy
  • 14.6 Cytori Therapeutics
    • 14.6.1 Company Products
    • 14.6.2 Financial Analysis
    • 14.6.3 Company Strategy
  • 14.7 MEDIPOST
    • 14.7.1 Company Details
    • 14.7.2 Company Products
      • 14.7.2.1 CellTree Umbilical Cord Blood Bank
      • 14.7.2.2 CARTISTEM®
      • 14.7.2.3 NEUROSTEM®
      • 14.7.2.4 PNEUMOSTEM ®
    • 14.7.3 Financial Analysis
  • 14.8 Mesoblast
    • 14.8.1 Company Details
      • 14.8.1.1 Unique Features of Mesoblast and its Disruptive Technology
      • 14.8.1.2 Allogeneic Mesenchymal Lineage Adult Stem Cells (MLCs)
      • 14.8.1.3 Mechanism of Action of MLC Products
      • 14.8.1.4 Manufacturing of Mesoblast MLC-Based Products
      • 14.8.1.5 Mesoblast Patent Portfolio
    • 14.8.2 Mesoblast Product Portfolio
      • 14.8.2.1 MSC-100-IV/TEMCELL® for Acute Graft Versus Host Disease (aGVHD)
      • 14.8.2.2 MPC-150-IM - Chronic Heart Failure (CHF)
      • 14.8.2.3 MPC-25-IC for Acute Myocardial Infarction
      • 14.8.2.4 MPC-06-ID - Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD)
      • 14.8.2.5 MPC-300-IV for Biologic-Refractory Rheumatoid Arthritis
      • 14.8.2.6 MPC-300-IV for Diabetic Nephropathy
      • 14.8.2.7 MPC-100-IV for Crohn's Disease
      • 14.8.2.8 MPC-25-Osteo for Spinal Fusion
    • 14.8.3 Mesoblast International Strategic Business Collaborations
    • 14.8.4 Mesoblast Financial Analysis
  • 14.9 NuVasive
    • 14.9.1 Company Details
    • 14.9.2 Biologic Products for the Spinal Surgery Market
      • 14.9.2.1 Formagraft
      • 14.9.2.2 AttraX
      • 14.9.2.3 Propel DBM
      • 14.9.2.4 Osteocel Plus and Pro
    • 14.9.3 Financial Analysis
    • 14.9.4 Company Business Strategy
  • 14.10 Osiris Therapeutics
    • 14.10.1 Company Profile
      • 14.10.1.1 BioSmart Cryopreservation Technology
      • 14.10.1.2 MSC Primer Technology
    • 14.10.2 Products
      • 14.10.2.1 Grafix
      • 14.10.2.2 BIO 4
      • 14.10.2.3 Cartiform
      • 14.10.2.4 Stravix
    • 14.10.3 Company Financial Analysis
    • 14.10.4 Company Strategy
  • 14.11 Plasticell
    • 14.11.1 Company Profile
  • 14.12 Pluristem Therapeutics
    • 14.12.1 Company Profile
    • 14.12.2 Products
      • 14.12.2.1 PLacental eXpanded (PLX) Cells
      • 14.12.2.2 PLX-PAD
      • 14.12.2.3 PLX-R18
    • 14.12.3 Financial Analysis
    • 14.12.4 Business Strategy
  • 14.13 Pfizer
    • 14.13.1 Company Profile
  • 14.14 StemCells Inc
    • 14.14.1 Company Profile
    • 14.14.2 HuCNS-SC Platform Technology
    • 14.14.3 Clinical Trial Analysis
    • 14.14.4 Financial Analysis
  • 14.15 STEMCELL Technologies
    • 14.15.1 Company Details
    • 14.15.2 Product Details
  • 14.16 Takara Bio
    • 14.16.1 Company Details
    • 14.16.2 Product Portfolio
      • 14.16.2.1 HF10 Anti-Cancer Therapy
      • 14.16.2.2 TCR Gene Therapy
      • 14.16.2.3 MazF Gene Therapy
    • 14.16.3 Centre for Cell and Gene Processing
    • 14.16.4 Company Financials
    • 14.16.5 Company Strategy
  • 14.17 Tigenix
    • 14.17.1 Company Background
    • 14.17.2 Products
    • 14.17.3 Financial Data
    • 14.17.4 Company Strategy

15.0 SWOT Industry Analysis

  • 15.1 What has Strengthened the Industry Thus Far?
  • 15.2 Allogenic and Autologous Stem Cell Industry SWOT Analysis
  • 15.3 What are the Main Driving Forces of this Space?
  • 15.4 Restraints of the Regenerative Medicine Industry as a Whole
  • 15.5 Industry Opportunities Within this Sector
  • 15.6 USA SWOT Analysis
    • 15.6.1 Growth Opportunities
    • 15.6.2 Drivers
    • 15.6.3 Market Challenges
  • 15.7 UK SWOT Analysis
    • 15.7.1 Growth Opportunities
    • 15.7.2 Drivers
    • 15.7.3 Market Challenges
  • 15.8 South Korea SWOT Analysis
    • 15.8.1 Growth Opportunities
    • 15.8.2 Drivers
    • 15.8.3 Market Challenges
  • 15.9 China SWOT Analysis
    • 15.9.1 Growth Opportunities
    • 15.9.2 Drivers
    • 15.9.3 Challenges
  • 15.10 Japan SWOT Analysis
    • 15.10.1 Opportunities
    • 15.10.2 Market Drivers
    • 15.10.3 Challenges
  • 15.11 Singapore SWOT Analysis
    • 15.11.1 Opportunities
    • 15.11.2 Market Drivers
    • 15.11.3 Challenges

List of Exhibits

  • Exhibit 2.1 Stem Cell Discovery and Development Timeline
  • Exhibit 2.2 Potential Therapeutic Uses of Stem Cells
  • Exhibit 2.3 Embryonic Stem Cell Differentiation
  • Exhibit 2.4 Pluripotent Stem Cells
  • Exhibit 2.5 Clinical Uses of Stem Cells
  • Exhibit 2.6 Illustration of Inner Cell Mass Generation for Stem Cell Culture
  • Exhibit 2.7 Drug Development Strategies for Patient Derived iPSCs
  • Exhibit 2.8 Mesenchymal Stem Cell Lineage Progression & Differentiation
  • Exhibit 2.9 Mesenchymal Stem Cell Differentiation
  • Exhibit 2.10 Potential Therapeutic Effects of MSCs
  • Exhibit 2.11 Hematopoietic Stem Cells & the Formation of Mature Blood Cells
  • Exhibit 2.12 Donor Types for HSC transplantation
  • Exhibit 2.13 Total Number of Stem Cell Donors 1989-Present
  • Exhibit 2.14 Cross Section of Umbilical Cord Sample for Stem Cell Extraction
  • Exhibit 2.15 Umbilical Cord Blood and Wharton's Jelly; Sources of HSCs and MSCs
  • Exhibit 2.16 Comprehensive List of Conditions Treated by Cord Blood Transplants
  • Exhibit 2.17 Cardiac Progenator Cell Populations
  • Exhibit 2.18 Transplanted Cardiac Progenitor Cells: Potential Mechanism of Action in the Myocardium
  • Exhibit 2.19 Mammary Stem Cells in the Presence and Absence of Hormones
  • Exhibit 2.20 Mammary Stem Cell Tree Following Transplantation
  • Exhibit 2.21 Production of Neurons, Astrocytes and Oligodendrocytes from Neural Stem Cells
  • Exhibit 2.22 Physiology of the Eye
  • Exhibit 2.23 Physiological Functions of Each Eye Component
  • Exhibit 2.24 Healthy & Degenerated Retinal Pigment Epithelium
  • Exhibit 2.25 Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium
  • Exhibit 2.26 Using Stem Cells to Replace Dysfunctional Retinal Pigment Epithelial Cells
  • Exhibit 2.27 Using Stem Cells to Replace Retinal Nerve Cells
  • Exhibit 2.28 Stem Cells Located Around the Central Vein in the Liver
  • Exhibit 2.29 Gut Stem Cells are Located in the Crypts of Lieberhahn
  • Exhibit 2.30 Localization of Epidermal & Dermal Stem Cells
  • Exhibit 3.1 Current Therapeutic Areas and Disease States with Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.2 Current Geographical Location and Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.3 Current Geographical Location and Number of Stem Cell Clinical Trials, USA
  • Exhibit 3.4 Current Geographical Location and Number of Stem Cell Clinical Trials, Europe
  • Exhibit 3.5 Current Geographical Location and Number of Stem Cell Clinical Trials, East Asia
  • Exhibit 3.6 Select hESC and iPSC-Based Products in Clinical Trials by Disease, Stage and Trial Status
  • Exhibit 3.7 Selected Studies and Key Findings of PSC-Based Therapies in Development for AMD, Diabetes, Liver Disease, Parkinson's and Thalassemia
  • Exhibit 3.8 Ocata Therapeutics Current Stem Cell Trials, Globally
  • Exhibit 3.9 CHA Biotech Current Stem Cell Trials, Globally
  • Exhibit 3.10 Pfizer Current Stem Cell Trials, Globally
  • Exhibit 3.11 GSK Current Stem Cell Trials, Globally
  • Exhibit 3.12 Bayer Current Stem Cell Trials, Globally
  • Exhbit 3.13 Mesoblast International Current Stem Cell Trials, Globally
  • Exhibit 3.14 Millennium Pharmaceutical Current Stem Cell Trials, Globally
  • Exhibit 3.15 AstraZeneca Current Stem Cell Trials, Globally
  • Exhibit 3.16 Merck Current Stem Cell Trials, Globally
  • Exhibit 3.17 Chimerix Current Stem Cell Trials, Globally
  • Exhibit 3.18 Eisai Current Stem Cell Trials, Globally
  • Exhibit 3.19 SanBio Current Stem Cell Trials, Globally
  • Exhibit 3.20 Celgene Current Stem Cell Trials, Globally
  • Exhibit 3.21 StemCells Current Stem Cell Trials, Globally
  • Exhibit 3.22 Genzyme (Sanofi) Current Stem Cell Trials, Globally
  • Exhibit 3.23 Teva Current Stem Cell Trials, Globally
  • Exhibit 3.24 MedImmune Current Stem Cell Trials, Globally
  • Exhibit 3.25 Janssen Current Stem Cell Trials, Globally
  • Exhibit 3.26 Seattle Genetics Current Stem Cell Trials, Globally
  • Exhibit 3.27 Baxter Healthcare Current Stem Cell Trials, Globally
  • Exhibit 3.28 InCyte Corp Current Stem Cell Trials, Globally
  • Exhibit 4.1 Disease Models Generated from iSPC using Genome Editing
  • Exhibit 4.2 Stem Cells Used for Drug Screening
  • Exhibit 4.3 Sucessful Human iPSC Mediate Therapy Cases
  • Exhibit 4.4 Number of US Patients That Could Benefit From Stem Cell Therapeutics
  • Exhibit 4.5 Genentechs Stem Cell Platform for Drug & Toxicity Screening
  • Exhibit 4.6 Key Challenges in Assessing Genetic Instability of Stem Cells
  • Exhibit 4.7 Comprehensive In Vitro Proarrhythmia Assay (CiPA) Components
  • Exhibit 4.8 Ex Vivo Gene Therapy and Stem Cell Technology
  • Exhibit 4.9 Genome Editing and iPSCs
  • Exhibit 4.10 Gene Edited iPSC/hES-Mediated Novel Therapy Development
  • Exhibit 4.11 Comparison of 3D and 2D Cultures of iPSC-Derived Hepatocytes Following Treatment with Toxins, Anti-Proliferative Agents and Other Drugs
  • Exhibit 4.12 Potential Applications of Human iPSCs for Liver Diseases
  • Exhibit 4.13 Myocardial Tissue: Cardiomyocytes, Endothelial Cells and Fibroblasts
  • Exhibit 4.14 Cardiovascular Disease-Specific Human Pluripotent Stem Cell Lines by Genetic Cause and Drug Testing
  • Exhibit 4.15 Culture of Human iPSC-Derived Dopaminergic Neurons over 14 Days
  • Exhibit 4.16 Strategies for Generating Disease Models Using Human Pluripotent Stem Cells (PSCs)
  • Exhibit 4.17 Criteria for Disease Modelling Using Pluripotent Stem Cells
  • Exhibit 4.18 Models of Monogenic Dominant Diseases
  • Exhibit 4.19 Models of Monogenic Recessive Diseases
  • Exhibit 4.20 Models of Monogenic X-linked Recessive Diseases
  • Exhibit 4.21 iPSCs in Neurological Disease Modeling, Drug Screening & Cell Therapy
  • Exhibit 4.22 Advantages and Uses of Intestinal Organoids
  • Exhibit 5.1: Main Biomarkers Associated with Pluripotent Stem Cells
  • Exhibit 5.2: Pluripotent Stem Cell Biomarkers
  • Exhibit 5.3 Main Biomarkers Associated with Mesenchymal Stem Cells
  • Exhibit 5.4 Mesenchymal Stem Cell Biomarkers
  • Exhibit 5.5 Main Biomarkers Associated with Neural Stem Cells
  • Exhibit 5.6 Neural Stem Cell Biomarkers
  • Exhibit 5.7 Main Biomarkers Associated with Hematopoietic Stem Cells
  • Exhibit 5.8 Hematopoietic Stem Cell Biomarkers
  • Exhibit 6.1 Bioprocess Development Considerations for hPSC-Derived Products
  • Exhibit 6.2 Technologies Used for Expansion & Differentiation of hPSC-Derived Cell Products
  • Exhibit 6.3 Comparison of Key Performance Characteristics of Cardiomyocytes, Hepatocytes, Neurons, Neural Progenitor Cells, Endoderm Progenitors and Hepatocytes in Planar & Bioreactor Based Differentiation Protocols
  • Exhibit 6.4 Integrated Expansion & Differentiation of hPSCs Studies by Cell, Process, Cell Density, Process Time and Target Cells Produced
  • Exhibit 6.5 hPSC Bioprocess Strategies, Planar, Segregated 3D & Integrated: Advantages & Disadvantages
  • Exhibit 6.6 Main Objectives of GMP Manufacturing
  • Exhibit 6.7 GMP Facilities Required for Stem Cell Product Manufacuring
  • Exhibit 6.8 Manufacturing Overview of hIPSCs under GMP Regulation
  • Exhibit 6.9 Key Steps in Manufacturing GMP Regulated iPSCs
  • Exhibit 6.10 Characterization and Release Assays for Human iPSCs Manufactured under GMP Conditions
  • Exhibit 6.11 MCB Viral Assays for use on Human iPSCs Bank
  • Exhibit 6.12 Differences Between Autologous & Allogeneic Cell Therapy Models
  • Exhibit 7.1 Selected Venrock Biotech and Healthcare Exits
  • Exhibit 7.2 Stem Cell Funding Bodies, Globally
  • Exhibit 7.3 Stem Cell Societies and Consortiums by Geography
  • Exhibit 7.4 Total Stem Cell NIH Funding 2014-2017
  • Exhibit 7.5 NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.6 Tabular Data NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.7 CIRM Investment Funding by Stem Cell Type
  • Exhibit 7.8 CIRM Stem Cell Project Investment Funding by Therapeutic Area
  • Exhibit 7.9 Promising Cell & Gene Companies
  • Exhibit 8.1 Global Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.2 GeoMap Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.3 Increased Proportion of People Over 65 Through 2050
  • Exhibit 8.4 Percentage of Global Population Aged 65 Plus 2015-2050
  • Exhibit 8.5 Global Alzheimer's Disease Market Forecast
  • Exhibit 8.6 Global Cardiovascular Market Forecast
  • Exhibit 8.7 Global Diabetes Therapy and Device Market Forecast
  • Exhibit 8.8 Bone Graft Global Market Forecast
  • Exhibit 8.9 Bone Graft Global Market Forecast by Geography
  • Exhibit 8.10 Total Global Financings of the Regenerative Medicine, Cell and Gene Therapy and Tissue Engineering Sector
  • Exhibit 8.11 Total Global Financing of Regenerative Medicine & Cellular/Gene Therapy by Type
  • Exhibit 8.12 Number of Global Clinical Trials by Phase of Regenerative Medicine, Cell and Gene Therapy Studies
  • Exhibit 8.13 Number of Global Clinical Trials by Indication of Regenerative Medicine, Cellular & Gene Therapeutics
  • Exhibit 8.14 Major Clinical Trial Events in Regenerative Medicine
  • Exhibit 8.15 Global Regenerative Medicine Market Value Tabular Forecast to 2025
  • Exhibit 8.16 Global Regenerative Medicine Market Value Forecast to 2025
  • Exhibit 8.17 Regenerative Medicine Geographic Analysis and Forecast to 2025
  • Exhibit 8.18 Regenerative Medicine Geographic Forecast Table to 2025
  • Exhibit 8.19 Regenerative Medicine Market Share by Geography 2019
  • Exhibit 8.20 Regenerative Medicine Market Share Forecast by Geography 2025
  • Exhibit 8.21 North America Regenerative Medicine Forecast to 2025
  • Exhibit 8.22 European Regenerative Medicine Forecast to 2025
  • Exhibit 8.23 Asia Pacific Regenerative Medicine Forecast to 2025
  • Exhibit 8.24 RoW Regenerative Medicine Forecast to 2025
  • Exhibit 8.25 Geographical Location of Regenerative Medicine Companies
  • Exhibit 8.26 Regenerative Medicine Technology Breakdown of Companies
  • Exhibit 8.27 Number and Geographical Location of Regenerative Medicine, Cellular Therapy & Gene Therapy Companies, Globally
  • Exhibit 8.28 Select FDA-Approved Regenerative Medicine Products by Biologics. Cell Based and Biopharmaceuticals
  • Exhibit 8.29 Regulatory Approved & Commercialized Regenerative Medicine Products Currently on the Market
  • Exhibit 8.30 Major Regenerative Medicine Milestones
  • Exhibit 9.1 Global Stem Cell Therapy Market Forecast Table to 2025
  • Exhibit 9.2 Global Stem Cell Therapy Market Forecast to 2025
  • Exhibit 9.3 Stem Cell Market Share by Adult and Embryonic Stem Cells and Stem Cell Banking
  • Exhibit 9.4 Major Clinical Trial Events in Stem Cell Medicine
  • Exhibit 9.5 Stem Cell Geographic Market Share Forecast to 2025
  • Exhibit 9.6 Global Stem Cell Market Share by Geographic Region 2019
  • Exhibit 9.7 Global Stem Cell Market Share by Geographic Region 2025
  • Exhibit 9.8 North American Stem Cell Market Forecast to 2025
  • Exhibit 9.9 Asia Pacific Stem Cell Market Forecast to 2025
  • Exhibit 9.10 European Stem Cell Market Forecast to 2025
  • Exhibit 9.11 Rest of the World Stem Cell Market Forecast to 2025
  • Exhibit 9.12 Market Share of Top Therapeutic Indications in Stem Cell Space, 2019
  • Exhibit 9.13 Market Share of Top Therapeutic Indications in Stem Cell Space, 2025
  • Exhibit 9.14 Stem Cell Market Forecast by Therapeutic Indications to 2025
  • Exhibit 9.15 Orthopedic/Musculoskeletal Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.16 Cancer Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.17 Cardiology/Vascular Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.18 Wound Healing Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.19 Skin Stem Cell Products and Sources
  • Exhibit 9.20 Skin Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.21 Ocular Stem Cell SubMarket Forecast to 2025
  • Exhibit 9.22 Current Top Brands Being Used for Stem Cell R&D
  • Exhibit 9.23 Most Frequent Method of Obtaining Stem Cell Lines in R&D
  • Exhibit 9.24 Percentage of Stem Cell Characterization Analysis Kits Used in R&D
  • Exhibit 9.25 Percentage of Stem Cell Differentiation Kits Used in R&D
  • Exhibit 9.26 Most Common Types of Stem Cells Used in R&D by Mouse, Human & Rat Origin
  • Exhibit 10.1 Global Tissue Engineering Market Tabular Forecast to 2025
  • Exhibit 10.2 Global Tissue Engineering Market Forecast to 2025
  • Exhibit 10.3 Global Tissue Engineering Market Forecast by Geographic Region to 2025
  • Exhibit 10.4 North America Tissue Engineering Market Forecast to 2025
  • Exhibit 10.5 Europe Tissue Engineering Market Forecast to 2025
  • Exhibit 10.6 Asia Pacific Tissue Engineering Market Forecast to 2025
  • Exhibit 10.7 Geographical Breakdown of Tissue Engineering Companies Globally
  • Exhibit 10.8 Public and Privately Held Tissue Engineering Company Distribution, Globally
  • Exhibit 10.9 Main Players in the Tissue Engineering Market
  • Exhibit 10.10 Main Players in the CAR-T Market
  • Exhibit 10.11 Main Players in the TCR Market
  • Exhibit 10.12 Main Players in the NK Cell Market
  • Exhibit 10.13 Main Players in the TILs Market
  • Exhibit 10.14 Global Tissue Engineering Submarket Breakdown by Market Share 2019
  • Exhibit 10.15 Global Tissue Engineering Submarket Breakdown by Market Share Forecast 2025
  • Exhibit 10.16 Tissue Engineering Submarket Breakdown Forecast Table to 2025
  • Exhibit 10.17 Tissue Engineering Submarket Breakdown Forecast to 2025
  • Exhibit 10.18 Orthopedics/Musculoskeletal Tissue Engineering Market Forecast to 2025
  • Exhibit 10.19 Oncology Tissue Engineering Market Forecast to 2025
  • Exhibit 10.20 Cardiology and Vascular Tissue Engineering Market Forecast to 2025
  • Exhibit 10.21 Dermatology Tissue Engineering Market Forecast to 2025
  • Exhibit 10.22 Oral and Dental Tissue Engineering Market Forecast to 2025
  • Exhibit 11.1 Number of Stem Cell Donors by Geographical Location
  • Exhibit 11.2 Number and Geographical Location of Global Unrelated Cord Blood Units
  • Exhibit 11.3 Market Share of Companies in the BioBanking Industry
  • Exhibit 11.4 Market Share within Therapeutic Companies in the BioBanking Industry
  • Exhibit 11.5 Market Share within Cell & Tissue Banks in the BioBanking Industry
  • Exhibit 11.6 Percentage of Allogenic & Autologous Transplantations
  • Exhibit 11.7 Percentage Breakdown of Indications using Autologous Umbilical Cord Blood Transplants
  • Exhibit 11.8 Percentage Breakdown of Indications using Allogenic Umbilical Cord Blood Transplants
  • Exhibit 11.9 Global Cord Blood Banking Market Forecast to 2025
  • Exhibit 11.10 Stem Cell Biobanking Market Segments
  • Exhibit 11.11 Top Global Cord Blood and Tissue Companies
  • Exhibit 11.12 Important Players in the International Private Cord Bank Market
  • Exhibit 12.1 Key Challenges to the Regenerative Medicine & Cellular/Gene Therapy Market
  • Exhibit 12.2 Company and Indication that will Benefit from New 21st Century Cures Act, USA
  • Exhibit 12.3 Cell and Gene Based Therapy in Japan as Defined by the PMDA
  • Exhibit 12.4 Regulatory System in Japan for Regenerative Medicine and Cell and Gene Therapy Products
  • Exhibit 12.5 Main Stem Cell Research Institutes in China
  • Exhibit 13.1 Selected CD19-directed Product Candidates in Clinical Trials by Costimulatory & Binding Domains, Starting Cell Population, Vector and Ablation Technology
  • Exhibit 13.2 Select CD19-Directed ALL Clinical Trials
  • Exhibit 13.3 Select Anti-CD22 CAR-T Clinical Projects
  • Exhibit 13.4 CBER Compliance and Surveillance Activities
  • Exhibit 13.5 Contacts for the Cellular, Tissue and Gene Therapies Advisory Committee, FDA
  • Exhibit 13.6 Clinical Regulatory Pathway - Conventional Route
  • Exhibit 13.7 Clinical Regulatory Pathway - Option for Rapid Translation
  • Exhibit 13.8 PMDA Total Review Period of Standard Drugs
  • Exhibit 13.9 PMDA Total Review Period of Priority Drugs
  • Exhibit 13.10 Number of Approved Recombinant Protein Products by PMDA
  • Exhibit 13.11 Forerunner Review Assignment System Timeframe
  • Exhibit 13.12 Adaptive Licensing and Accelerated Approval in Japan-US-EU
  • Exhibit 13.13 Key Contacts Within PMDA, Japan
  • Exhibit 13.14 CheckMate 066 Clinical Trial
  • Exhibit 13.15 CheckMate 037 Clinical Trial
  • Exhibit 13.16 Contact Details for EMA Cell Therapy & Immunotherapy Experts
  • Exhibit 13.17 Method of Generating CAR-Modified T Cells
  • Exhibit 13.18 Clinical Activity, Cost Structure and Patient Convenience Flow Chart of CAR-T Therapy
  • Exhibit 13.19 General Technical and Personnel Requirements of a GMP, QC, QA, FDA Regulated Cell Therapy Manufacturing Facility
  • Exhibit 13.20 Technician/Scientific Requirements for CAR T Manufacturing
  • Exhibit 13.21 Selection of Apheresis Instruments Currently on the Market
  • Exhibit 13.22 Selection of Cell Counters and Analyzer Instruments Currently on the Market
  • Exhibit 13.23 Main Objectives of GMP Manufacturing Immunotherapeutics
  • Exhibit 13.24 Main Objectives of Quality Control While Manufacturing Immunotherapeutics
  • Exhibit 13.25 Main Objectives of Regulatory Affairs During Manufacturing Immunotherapeutics
  • Exhibit 13.26 CAR-T Studies Using mRNA Transfection Electroporation
  • Exhibit 13.27 Allogenic Versus Autologous Cell Manufacturing
  • Exhibit 13.28 Challenges for Autologous Cell Therapy Manufacture
  • Exhibit 13.29 Current Company/Institutions with Suicide Gene CAR T Projects
  • Exhibit 13.30 Advantages of Using Automated Cell Therapy Manufacturing
  • Exhibit 13.31 Main Drivers to Implement Automated Cell Therapy Manufacturing
  • Exhibit 13.32 Main Benefits of Automated Cell Therapy Manufacturing
  • Exhibit 13.33 Advantages & Disadvantages of Autologous Cell Therapy Manufacture Scale Up
  • Exhibit 13.34 Streptamer® -Based Magnetic Bead Cell Isolation Exhibit 13.35 Juno Therapeutics Manufacturing Facility Objectives
  • Exhibit 13.36 Annual Cost of Patented Cancer Therapeutics from 2000 to Today
  • Exhibit 13.37 Cost of Nivolumab, Pembrolizumab & Ipilimumab per mg
  • Exhibit 13.38 Current Juno Therapeutics Trials and CAR T Products
  • Exhibit 13.39 Current CAR T Business Deals
  • Exhibit 13.40 Selected Antigens, Endomains and Gene Transfer Methods Used for CAR-T Therapy
  • Exhibit 13.41 Immunosuppressive Modulators in Tumor Microenvironment
  • Exhibit 13.42 Challenges for CAR-T therapy and Solid Tumors
  • Exhibit 13.43 Tumor Associated Antigens for CART Therapy by Tissue Type
  • Exhibit 13.44 Select Clinical Trials using CAR-T in Solid Tumors
  • Exhibit 14.1 MultiStem Platform in Action
  • Exhibit 14.2 Key Advantages of MultiStem
  • Exhibit 14.3 Athersys Product and Clinical Pipeline
  • Exhibit 14.4 Athersys Key Business Strategies
  • Exhibit 14.5 Baxter International Product Revenue by Class
  • Exhibit 14.6 Baxter International Product Revenue by Geography
  • Exhibit 14.7 Baxter International Breakdown of Product Revenue
  • Exhibit 14.8 Caladrius Expertise in Cell Type and Therapeutic Application Portfolio
  • Exhibit 14.9 PCT Caladrius CLBS03 Treg Cellular Therapy Manufacturing Process
  • Exhibit 14.10 Caladrius Revenue
  • Exhibit 14.11 Caladrius Clinical Manufacturing Revenue
  • Exhibit 14.12 Caladrius Process Development Revenue
  • Exhibit 14.13 Cytori Cell Therapy Mechanism of Action in Angiogenesis, Inflammation and Wound Remodeling
  • Exhibit 14.14 Cytori Therapeutics Cell Therapy Clinical Pipeline
  • Exhibit 14.15 MediPost Product Pipeline by Indication and Clinical Study Phase
  • Exhibit 14.16 Medipost Sales Figures
  • Exhibit 14.17 CellTree Umbilical Cord Blood Bank Program Details and Pricing
  • Exhibit 14.18 Medipost Revenue Share by Product Category
  • Exhibit 14.19 Medipost Sales Revenue by Product Category
  • Exhibit 14.20 Medipost Umbilical Cord Blood Bank Revenue
  • Exhibit 14.21 Medipost Stem Cell Drug Sales Revenue
  • Exhibit 14.22 Medipost R&D Investment
  • Exhibit 14.23 Mesenchymal Lineage Adult Stem Cells (MLCs) Secrete a Variety of Immunomodulatory Molecules
  • Exhibit 14.24 Mesoblast Mesenchymal Lineage Adult Stem Cell (MLC) Functional Properties
  • Exhibit 14.25 Mesoblast Expanion and Immune Privilege of MLC Technology
  • Exhibit 14.26 Mesoblast Complementary Technology Platforms
  • Exhibit 14.27 Mechanism of Action of MPC-150-IM, MPC-06-ID, MPC-300-IV, TEMCELL(R)HS. Inj. and MSC-100-IV and MPC-25-OSTEO
  • Exhibit 14.28 Mesoblast MLC-Based Product Manufacturing and Distribution Process
  • Exhibit 14.29 Mesoblast Patent Portfolio with Expiration and Validity through 2035
  • Exhibit 14.30 Mesoblast Tier 1 and Tier 2 Product Candidates by Program and Clinical Stage
  • Exhibit 14.31 Mesoblast Lead Product MSC-100-IV/TEMCELL HS Inj
  • Exhibit 14.32 MSC-100-IV Treatment in Children with SR-aGVHD who Failed Other Modalities
  • Exhibit 14.33 MPC-300-IV for Treatment of Chronic Inflammatory Diseases
  • Exhibit 14.34 Mesoblast International Strategic Business Collaborations
  • Exhibit 14.35 Mesoblast Share Price and Financial Analysis
  • Exhibit 14.36 Mesoblast Revenue Generated
  • Exhibit 14.37 Mesoblast R&D Expenditure
  • Exhibit 14.38 NuVasive Biologics Portfolio
  • Exhibit 14.39 NuVasive Global Revenue
  • Exhibit 14.40 NuVasive NON GAAP Operating Profit Margin
  • Exhibit 14.41 NuVasive Spinal Surgery Product and Biologic Revenue Breakdown
  • Exhibit 14.42 NuVasive USA and International Revenue Breakdown
  • Exhibit 14.43 NuVasive Corporate Strategy Going Forward
  • Exhibit 14.44 Osiris Therapeutics Current Product Portfolio
  • Exhibit 14.45 Osiris Therapeutics Product Pipeline by Indication, Preclinical, Clinical and Market Stage
  • Exhibit 14.46 Exhibit Plasticel Partnerships and Collaborations with Industry and Academic Institutions
  • Exhibit 14.47 Pluristem Therapeutics Company Pipeline Portfolio by Product, Indication, Location & Phase
  • Exhibit 14.48 Pluristem Therapeutics Production of PLX-PAD & PLX-R18
  • Exhibit 14.49 Pluristem Therapeutics Revenue
  • Exhibit 14.50 Pluristem Therapeutics R&D Costs
  • Exhibit 14.51 Pfizer Stem Cell Policy
  • Exhibit 14.52 StemCell Inc Manufacturing Steps of Hu-CNS-SC Product
  • Exhibit 14.53 STEMCELL Technologies Product Portfolio
  • Exhibit 14.54 STEMCELL Technologies Brand Portfolio
  • Exhibit 14.55 Takara Bio Sales Revenue
  • Exhibit 14.56 Takara Bio Operating Sales
  • Exhibit 14.57 Takara BioIndustry Sales Revenue
  • Exhibit 14.58 Takara Bio Sales by Geographic Region
  • Exhibit 14.59 Tigenix Key Intellectual Property Patent Portfolio
  • Exhibit 14.60 Comprehensive List of Companies in the Stem Cell & Regenerative Medicine Industry
  • Exhibit 15.1 Advantages, Weaknesses, Opportunities & Threats of Allogenic & Autologous Stem Cells
  • Exhibit 15.2 Opportunistic Therapeutic Indications as Decided by Senior Key Opinion Leaders
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.